Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6
You may also be interested in...
China Builds Up Capability To Conduct Oncology First-In-Man Studies
SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market
China Builds Up Capability To Conduct Oncology First-In-Man Studies
SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market
Chinese Government Venture Firm Funds JV To Explore Early-stage Oncology Trials
SHANGHAI- Texas-based South Texas Accelerated Research Therapeutics recently announced that it will partner with Shanghai-based venture capital fund Cenova Ventures to form a joint venture to conduct early-stage oncology trials for pharma companies on both sides of the Pacific